Literature DB >> 3875433

Intermediate-term results of coronary artery bypass grafting for acute myocardial infarction.

J K Kirklin, E H Blackstone, G L Zorn, A D Pacifico, J W Kirklin, R B Karp, W J Rogers.   

Abstract

To assess the intermediate-term results of emergency coronary revascularization for acute myocardial infarction, we analyzed all patients (n = 35) who underwent coronary artery bypass grafting within 48 hr of acute myocardial infarction between January 1, 1982, and March 1, 1983. All patients had complete revascularization of infarct and noninfarct areas (3.4 +/- 1.65 distal anastomoses per patient). All patients have been traced as of February 21, 1984. Median duration of follow-up was 17.4 months (range 11.2 to 23.7). One in-hospital death (2.9%, 70% confidence limits 0% to 9%) occurred with low cardiac output, and no deaths occurred in the four patients who were in cardiogenic shock before surgery. One late death occurred from cancer, and 1 year overall actuarial survival is 94%. One patient underwent successful cardiac transplantation 8 months after operation. Ninety-seven percent of surviving patients are in NYHA class I or II, and 82% (27/33) have had no postoperative angina; six patients have mild angina. No patient has suffered a subsequent myocardial infarction. The early and intermediate results support continued application of emergency revascularization in higher-risk subsets of patients with acute myocardial infarction.

Entities:  

Mesh:

Year:  1985        PMID: 3875433

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  2 in total

1.  [Indications in angina pectoris--surgical therapy].

Authors:  P Satter
Journal:  Langenbecks Arch Chir       Date:  1986

2.  Clinical outcome of urgent coronary artery bypass grafting.

Authors:  Do-Kyun Kim; Kyung-Jong Yoo; You Sun Hong; Byung-Chul Chang; Meyun-Shick Kang
Journal:  J Korean Med Sci       Date:  2007-04       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.